Home > Business Cases > Helping investors de-risking due dilligence
Helping investors de-risk due dilligence
-
A European VC wants to invest in a small pharma that has developed 2 compounds: XYZ_1 and XYZ_2 as HDAC inhibitors.
-
They want to select only one compound to move forward, mainly based on the safety profile.
-
Anaxomics conducts the comparison of the safety profile between the 2 compounds, and compares them with the class.
-
Anaxomics technology predicts safety profile of known compounds with >90% accuracy based on the compound's target profile (different HDAC isoforms).
-
Safety profile of new compounds XYZ is predicted with the same degree of accuracy.
-
VC decides to invest in the compound with the best safety profile, now on safer grounds.
Positioning of Drug A and Drug B in comparison with other molecules in class.
Please, contact us here to request more information.
